Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO), a Delaware corporation headquartered in Seattle, Washington, filed this Form 8-K on April 21, 2025. The report details a registered direct offering of common stock completed on April 22, 2025.
Key Financial Metrics
- Offering Size: 2,324,000 shares of Common Stock.
- Purchase Price: $0.862 per share.
- Gross Proceeds: Approximately $2.0 million (calculated as 2,324,000 shares x $0.862).
- Net Proceeds: Approximately $1.8 million after deducting offering expenses and placement agent fees.
- Placement Agent Fee: 7.0% of aggregate gross proceeds paid to Roth Capital Partners, LLC.
- Use of Proceeds: Working capital to fund clinical programs, general corporate purposes, and further development of product candidates.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock by 2,324,000 shares and the influx of approximately $1.8 million in net cash. The Company entered into a lock-up agreement restricting the issuance of additional common stock or convertible securities for five days following the Closing Date.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance clinical programs and support general corporate operations. The filing references customary representations, warranties, and indemnification obligations within the Purchase Agreement. No specific forward-looking financial guidance or new risk factors were disclosed in this specific report beyond standard offering terms.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the total cash balance and runway extension provided by the $1.8 million net proceeds.
- Review the attached Securities Purchase Agreement (Exhibit 10.2) for specific investor rights or covenants.
- Monitor the five-day lock-up period expiration for potential additional equity issuance.